期刊文献+

糖尿病足患者血清同型半胱氨酸及胱抑素C水平变化的研究 被引量:1

Changes of Serum Homocysteine and Cystatin C levels in Patients with Diabetic Foot
原文传递
导出
摘要 目的探讨糖尿病足患者血清同型半胱氨酸、胱抑素C水平变化的临床特点。方法将2015年12月-2017年3月收治的90例患者分为轻度组、中度组、重度组糖尿病足患者及对照组糖尿病未并发糖尿病足患者均接受血清同型半胱氨酸、胱抑素C检测,记录各组检测结果,将所得数据输入SPSS 19.0软件后给予统计学分析并得出结论。结果对照组糖尿病未发生糖尿病足患者血清同型半胱氨酸、胱抑素C水平最低,重度组糖尿病足患者上述各项指标检测值最高(P<0.05)。结论血清同型半胱氨酸、胱抑素C水平与糖尿病足的发生、发展具有密切关系,应用血清同型半胱氨酸、胱抑素C检测值有利于提高糖尿病足诊断率及判断疾病程度准确性。 Objective To investigate the serum of patients with diabetic foot clinical characteristics of homocysteine,Cystatin C level changes.Methods The 90 patients who were eated from December 2015 to March 2013 were divided to mild group,moderate group and severe group of diabetic foot patients and the control group without diabetic foot patients complicated with diabetes were treated with serum homocysteine,Cystatin C,recorded test results,the data input SPSS19.0 software after giving statistical analysis and conclusion.Results In the control group without the occurrence of diabetes in patients with diabetic foot serum homocysteine,Cystatin C,the lowest level in severe group of patients with diabetic foot on the detection of the index value is highest(P<0.05).Conclusion Serum Homocysteine and cystatin C levels are closely related to the occurrence and development of diabetic foot.The detection of serum homocysteine and cystatin C is helpful to improve the diagnostic accuracy of diabetic foot and to determine the degree of accuracy of the disease
作者 刘雨松 王强
出处 《双足与保健》 2017年第17期1-2,共2页 Biped and Health
关键词 糖尿病足 血清同型半胱氨酸 胱抑素C 临床特点 Diabetic foot Serum homocysteine Cystatin C Clinical characteristics
  • 相关文献

参考文献2

二级参考文献18

  • 1Dyck PJ.Detection,characterization,and staging of polyneuropathy:assessed in diabetics.Muscle Nerve,1988,11:21-32.
  • 2Forst T,Kann P,Pfutzner A,et al.Association between diabetic thick skin syndrome' and neurological disorders in diabetes.Acta Diabetol,1994,31:73-77.
  • 3Ewing DJ,Martyn CN,Young RJ,et al.The evalue of cardiovascular automic function tests:10 year experience in diabetes.Diabetes Care,1985,8:491-498.
  • 4Dyck PJ,Litchy WJ,Lehman KA,et al.Variables influencing neuropathic endpoints:the Rochester Diabetic Neuropathy Study of Healthy Subjects (RDNS-HS).Neurology,1995,45:1115-1120.
  • 5Ambrosch A,Dierkes J,Lobmann R,et al.Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus.Diabetic Medicine,2001,18:185-192.
  • 6Hofmann MA,Kohl B,Zumbach MS,et al.Hyperhomocysteinemia and endothelial dysfunction in IDDM.Diabetes Care,1998,21:841-848.
  • 7Stracke H,Lindemann A,Federlin K,et al.A benfotiaminevitamin B combination in treatment of diabetic polyneuropathy.Exp Clin Endocrin Diab,1996,104:311-316.
  • 8The Diabetes Control and Complications Trial Research Group.Factors in the development of diabetic neuropathy; baseline analysis of neuropathy in the feasibility phase of the Diabetes Control Complications Trial (DCCT).Diabetes,1988,37:476-481.
  • 9The Diabetes and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development of progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med,1993,329:977-986.
  • 10Wall RT,Harlan JM,Harker LA,et al.Homocysteineinduced endothelial cell injury in vitro:a model for the study of vascular injury.Thromb Res,1980,18:113-121.

共引文献42

同被引文献10

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部